Gastrointestinal stromal tumors. Report of two cases

Roberto Pérez-García; Carlos Alberto Xochipostequi-Muñoz

2007, Number 6

<< Back Next >>

Cir Cir 2007; 75 (6)

Gastrointestinal stromal tumors. Report of two cases

Pérez-García R, Xochipostequi-Muñoz CA

Full text

How to cite this article

Language: Spanish
References: 19
Page: 471-475
PDF size: 125.00 Kb.

ABSTRACT

Objective: We undertook this study to describe two cases of intestinal gistoma histologically and immunochemically proven.
Clinical cases: The study took place at a third level health care hospital in Mexico. Case 1. We report the case of a 39-year-old female with 4 years evolution of lower abdominal pain and with a 16-cm tumoral mass. The patient reported a 28-kg weight loss during the previous 6 weeks. Ultrasound revealed a left adnexal mass (12 × 17 × 15 cm) and CA125 tumor marker value of 4 ng/ml. Laparotomy identified a 15-cm intestinal mass with metastasis to mesentery, diaphragm and bladder. Palliative resection was performed of the small bowel, intestinal mass and termino-terminal anastomosis. Case 2. We report the case of a 37-year-old female with digestive hemorrhage (hematoquezy) during a period of 3 years who needed a blood transfusion on several occasions. The most recent transfusion was 2 days prior to her hospitalization. Physical examination did not reveal any abnormalities; hemoglobin was 8.3 g/dl, platelets 135,000/dl and white blood cells 8.8/dl. Abdominopelvic ultrasound revealed polycystic ovaries, technetium-99 nuclear scan revealed the presence and persistence of Meckel diverticulum. Laparotomy showed intestinal mass of 5 × 5 cm, 70 cm from Treitz angle. We used a wide intestinal resection, proximal and distal from the mass and termino-terminal anastomosis. Histochemical study was CD34 positive.
Conclusions: Gistomas are tumors of the gastrointestinal tract that are difficult to diagnosis because they are located in the submucosa. Treatment for primary tumor is surgical. Treatment for recurrent or metastatic GIST is imatinib or, if the patient is allergic to imatinib, another new tyrosine kinase inhibitor such as subitinib may be used. Definitive diagnosis is made by immunohistochemistry against CD117, and CD34, in the same manner as our cases.

REFERENCES

Nishida T, Hirota SL. Biological and clinical review of stromal tumor in the gastrointestinal tract. Histol Histopathol 2000;15:1293-1301.
2. Kindblom LG Meis-Kindblom J, Bummine P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST): a population-based study of 600 cases. Ann Oncol 2002;13:157.
3. Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology 2003;7:1615-1620.
4. Eisenberg BL. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-475.
5. Gold J, DeMateo RP. Combined surgical and molecular therapy: the gastrointestinal stroma tumor model. Ann Surg 2006:244:176-184.
6. Harvey JC, Beatle E. Cancer Surgery. 1st ed. Philadelphia: WB Saunders;1996. pp. 53-87.
7. Bifulco V, Profili S, Conti M, Meloni GB, Rovasio SS, Nieddu LA, Canalis GC. Diagnostic imaging of gastrointestinal leiomiosarcoma. Experience with 12 cases. Radiol Med (Torino) 1998;96:470-479.
8. North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am Surg 2000;66:46-51.
9. Wilson JM Melvin DB, Gray GF, et al. Primary malignancies of small bowel. Ann Surg 1974;179:175-181.
10. Fiora E, Ansali A, Galati G, Graziano P, Drudi FM, Maccioni F, Cangemi V. Leiomyosarcoma in jejunal diverticulum. A case report and review of the literature. G Chir 1996;17:269-275.
11. Ng Eh, Pollock RE, Musell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcoma. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
12. Kimura H, Yonemura Y, Kadoya N, et al. Prognostic factors in primary gastrointestinal leiomyosarcoma: a retrospective study. World J Surg 1991;15:771-777.
13. Kindblom LG. Gastrointestinal stromal tumors; diagnosis epidemiology, prognosis. ASCO Annual Meeting. Chicago;2003.
14. Durazo ET. Hemorragia gastrointestinal de origen obscure. Rev Gastrointestinal Mex 2006;71:54-55.
15. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-59.
16. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
17. Demitri GO, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanism in patients with metastatic gastrointestinal stroma tumor (GIST). J Clin Oncol 2004;22(14 Suppl):3001.
18. Desai J, Fakir, Heinrich MC, et al. Activity and tolerability of the multitargeted tyrosine kinase inhibitor SU11248 in patients with metastatic gastrointestinal tumor (GIST) refractory to imatinib mesylate. Gastrointestinal Cancers Symposium, San Francisco;2004.
19. Maki RG, Fletcher JA, Heinrich MC, et. al. Results from continuation trial of SU11248 in patients (PTS) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol 2003;23(16 suppl):9011.